TFL vs MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors

September 28, 2026 updated by: Ahmed Zakaria Ahmed, Thunder Bay Regional Health Research Institute

Thulium Fiber Laser (TFL) Versus MOSES Holmium Laser in the En-bloc Resection of Bladder Tumors: A Randomized Controlled Clinical Study

The goal of this randomized clinical trial is to determine if there is difference in pathological and clinical outcomes between MOSES and TFL in the transurethral laser enucleation of bladder tumors.

The main question it aims to answer is:

Is there a difference in pathological and clinical outcomes between MOSES Holmium and Thulium Fiber Laser (TFL) in the transurethral laser enucleation of bladder tumors?

Participants will randomized to either TFL of MOSES arm for their bladder resection procedure.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

An estimated 12,500 Canadians are diagnosed with bladder cancer each year. Diagnosis and treatment involve transurethral (through the urethra) resection of tumor or tissue called the TURBT procedure. This procedure yields excellent results and minimal morbidity and mortality but has a high recurrence rate, difficulties in the pathologic interpretation of the specimen (due to cautery effect), and procedure-related complications (excessive bleeding, bladder perforation, bowel injury, and inadvertent extensive injury to urethra) that may delay treatments such as chemotherapy which would further impact oncologic outcomes. With the advancement of technology, new methods of transurethral tumor removal have emerged, such as the use of laser energy. Using laser energy, the tumour is resected in one piece, whereas the TURBT approach requires breaking the tumor into pieces. This allows for better pathology analysis that can determine treatment pathways for the patient, as well as reduces the risk of complications. The standard lasers used have been the MOSES Holmium laser and the Thulium Fiber Laser (TFL).

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Thunder Bay, Ontario, Canada, P7B 6V4
        • Thunder Bay Regional Health Sciences Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Over 18 years of age at the time of enrollment.
  2. Patients presented with visual criteria suggesting bladder tumor by outpatient cystoscopy will be legible for inclusion.

Exclusion Criteria:

  1. Tumors deemed not eligible for laser resection as determined by the Urologist e.g. obvious muscle-invasive or metastatic at presentation
  2. Synchronous either urethral tumors or upper urinary tract tumor
  3. History of Carcinoma in situ
  4. Contracted bladder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Thulium Fibre Laser

Participants randomized to this arm will undergo bladder resection using the TFL laser

Participant undergoing bladder tumour resection that has been randomized to this arm.

Active Comparator: MOSES Holmonium

Participants randomized to this arm will undergo bladder resection using the MOSES holmium laser.

Participant undergoing bladder tumour resection that has been randomized to this arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Presence of muscularis propria
Time Frame: 1 day post-procesure

Presence of muscularis propria (bladder muscle cells) in the pathology sample of the bladder tumour

1 day post-procesure
Incidence of inconclusive pathology
Time Frame: 1 day post-procedure

Incidence of inconclusive pathology due to specimen artifact

1 day post-procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tumor-free rate (TFR)
Time Frame: 6 to 12 weeks post-procedure

As per the follow-up cystoscopy, TFR is defined as the absence of any residual tumor detectable by cystoscopy.

6 to 12 weeks post-procedure
Total operative time
Time Frame: Intraoperative

In minutes measured from anesthesia induction until placement of the urethral catheter

Intraoperative
Total procedural time
Time Frame: Intraoperative

In minutes, measured from the time the cystoscope sheath is inserted into the participant to the time the cystoscope has been removed

Intraoperative
Number of recurrences
Time Frame: 12 weeks post-procedure

Defined as any tumor detection by follow-up cystoscopy after the initial resection

12 weeks post-procedure
Total blood loss
Time Frame: 6 hours post-procedure

Defined as a drop in hemoglobin level from pre-op

6 hours post-procedure
Rate of complications
Time Frame: 4 weeks post-procedure

Percentage of participants with post-operative complications

4 weeks post-procedure
Number of inconclusive pathology
Time Frame: 1 day post-procedure

Number of inconclusive pathology due to thermal effect artifact.

1 day post-procedure
Lasing time
Time Frame: Intraoperative

In minutes, defined as the time the laser was in use, not including pedal pauses

Intraoperative
Total energy used
Time Frame: Intraoperative

Measured in kilojoules

Intraoperative
Frequency and severity of peri-operative complications
Time Frame: Intraoperative

Reported according to Clavien-Dindo

Intraoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Ahmed Z Ahmed, Thunder Bay Regional Health Sciences Centre

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 16, 2023

Primary Completion (Actual)

September 28, 2026

Study Completion (Actual)

September 28, 2026

Study Registration Dates

First Submitted

April 15, 2024

First Submitted That Met QC Criteria

April 17, 2024

First Posted (Actual)

April 18, 2024

Study Record Updates

Last Update Posted (Actual)

October 1, 2026

Last Update Submitted That Met QC Criteria

September 28, 2026

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • RP-1007

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.